Recent 8-K filings for DERM

• May 13, 2026, 4:06 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M

  Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.

• April 21, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Journey Medical expands Emrosi payer coverage to ~85% of US commercial lives after third GPO contract

  Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.

• March 25, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M

  Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.

• November 12, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%

  Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.

• August 12, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter

  Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.

• May 14, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway

  Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.

• March 26, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway

  Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.

• March 24, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Journey Medical launches Emrosi for rosacea; first prescriptions filled

  Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.

• November 12, 2024, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea

  FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.

• November 4, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 2.02item 8.01item 9.01

  FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged

  FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.

• August 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4

  Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.

• May 13, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024

  Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.

• March 21, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M

  Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

13 positive 0 negative 10 neutral

source · DERM on sec.gov